2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.42: Analysis of EGFR, ALK, ROS1, and PDL1 Biomarkers in Advanced Non-Small Cell Lung Cancer in Argentina

PP01.42: Analysis of EGFR, ALK, ROS1, and PDL1 Biomarkers in Advanced Non-Small Cell Lung Cancer in Argentina

Pdf Summary

The document provides an analysis of biomarker testing data for advanced Non-Small Cell Lung Cancer (NSCLC) patients from Argentina, collected between 2012 and 2023 through the Pfast lung biomarker database. Lung cancer, particularly NSCLC, is the leading cause of cancer-related deaths globally, accounting for over 1.7 million fatalities annually. Advances in genetic testing and targeted therapies have recently reduced NSCLC mortality by 15%, though data on genetic mutations in Latin America remains limited.<br /><br />This cross-sectional study analyzed clinical and molecular data from 12,209 Argentinian patients with advanced NSCLC, testing for EGFR, ALK, ROS1, and PD-L1. Key findings include high positivity rates for PD-L1 and varying positivity rates for EGFR and ALK, with EGFR showing a higher rate in Argentina's Northwestern region, possibly due to ethnic diversity.<br /><br />The median age of the study population was 68.4 years, with 55.5% female representation and 77.4% current smokers. Demographically, adenocarcinoma was present in 95.7% of the cases, with a significant number of biomarker tests concentrated in the AMBA region. EGFR mutation was more prevalent in females and non-smokers, while ALK and PD-L1 rates showed less variation. The study notes improved sample evaluability over time, reflecting increased awareness among healthcare providers.<br /><br />Overall, the study suggests that the biomarker incidence in Argentina aligns with broader Latin American data, underscoring its population representativity. Copositivity rates were generally consistent with existing literature, offering valuable insights into regional genetic variations that could enhance personalized treatment strategies for NSCLC patients in Argentina.

Asset Subtitle

Soledad Negrotto

Keywords

biomarker testing

NSCLC

Argentina

Pfast lung biomarker database

genetic testing

EGFR

ALK

PD-L1

adenocarcinoma

personalized treatment